Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
نویسندگان
چکیده
منابع مشابه
BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
Despite major advances in the treatment of metastatic melanoma, treatment failure is still inevitable in most cases. Manipulation of key epigenetic regulators, including inhibition of Bromodomain and extra-terminal domain (BET) family members impairs cell proliferation in vitro and tumor growth in vivo in different cancers, including melanoma. Here, we investigated the effect of combining the B...
متن کاملDabrafenib for treatment of BRAF-mutant melanoma
Melanoma has the highest mortality of all the skin cancer subtypes. Historically, chemotherapy and immunologic therapies have yielded only modest results in the treatment of metastatic melanoma. The discovery of prevalent V600 BRAF mutations driving proliferation makes this oncogenic protein an ideal target for therapy. Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response...
متن کاملDistinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
PURPOSE Certain clinicopathologic features correlate with BRAF mutation status in melanoma including younger age and primary subtype. This study sought to determine the BRAF mutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. METHODS A prospectively assembled cohort of Australian patients ...
متن کاملHuman Cancer Biology Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Purpose:Certain clinicopathologic features correlate with BRAFmutation status inmelanoma including younger age and primary subtype. This study sought to determine the BRAFmutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. Methods: A prospectively assembled cohort of Australian patients were...
متن کاملBRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free survival, compared to dabrafenib monotherapy, in a Phase II study and has received approval by th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Molecular Biosciences
سال: 2020
ISSN: 2296-889X
DOI: 10.3389/fmolb.2020.00172